Biogen Aktie

117,45 EUR -4,65 EUR -3,81 %

13:37:00

XETRA

129,89 USD -2,14 USD -1,62 %

vorbörslich14:44:57

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.17,49 Mrd. EUR

KGV13,67Div. Rendite0,00%

WKN789617

ISINUS09062X1037

SymbolBIIB

Biogen Aktien News

Sortieren:Datum Meistgelesen

02.04.25GlobeNewswireBiogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

24.03.25GlobeNewswireBiogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

11.03.25GlobeNewswireBiogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

WerbungBiogen-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

28.02.25PR NewswireThe Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

18.02.25GlobeNewswireBiogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and N

31.01.25GlobeNewswireUpdate on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

27.01.25GlobeNewswireFDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

27.01.25PR NewswireFDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

23.01.25GlobeNewswireFDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

14.01.25GlobeNewswireFDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

14.01.25PR NewswireFDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease

05.12.24PR Newswire"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico

28.11.24PR Newswire"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea

19.11.24GlobeNewswireDapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

14.11.24PR NewswireEisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease

14.11.24GlobeNewswireEisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

31.10.24GlobeNewswireEisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

29.10.24GlobeNewswireBiogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

29.10.24GlobeNewswireBiogen Appoints Daniel Quirk, MD, as Chief Medical Officer

28.10.24GlobeNewswireMichael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

27.10.24GlobeNewswireBiogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

24.10.24GlobeNewswireBiogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

22.10.24GlobeNewswireBiogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024

09.10.24GlobeNewswireBiogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients

08.10.24GlobeNewswireNew Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

24.09.24GlobeNewswireUCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

12.09.24GlobeNewswireBiogen Board Appoints Two New Independent Directors

04.09.24GlobeNewswireBiogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

22.08.24PR NewswireLeqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

31.07.24PR NewswireAlcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen

30.07.24GlobeNewswireNew Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alz

30.07.24PR NewswireNew Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The...

30.07.24GlobeNewswireBiogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

26.07.24GlobeNewswireUpdate on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

22.07.24PR NewswireBiogen Inc. Sued for Securities Law Violations - Contact the Schall Law Firm to Discuss Your Legal Rights BIIB

16.07.24PR NewswireBiogen Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BIIB

10.07.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB

10.07.24PR NewswireBiogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB

08.07.24PR NewswireShareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

02.07.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB

Biogen News

Biogen News: auf dieser Seite finden Sie alle Biogen News und Nachrichten zur Biogen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Biogen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Biogen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.